The Profitable IV Menu: How to Build, Price, and Source for Real Margin in 2026

Most IV menus are built backwards. Owners copy a competitor’s list, mark up the bag, and hope volume covers the rent. The clinics actually printing profit in 2026 do something different: they engineer the menu — anchor drips that fill chairs, premium add-ons that carry the margin, and a sourcing strategy that protects both.

The category rewards getting this right. The IV hydration market is projected to grow from roughly $2.83 billion in 2025 to $5.66 billion by 2033 (directional), and the fastest-growing slice is memberships, expanding north of 11% a year (directional). Here’s how to build a menu that captures it.

For adjacent decisions, see our 2026 IV therapy sourcing playbook, scaling mobile and membership IV models, adding NAD+ as a premium service, and the longevity IV compliance playbook.

Understand the Real Margin Math

The reason IV therapy looks so attractive is simple: the cost of goods is a small fraction of the price. Operator sources put supplies at roughly 10–15% of the service price. A hydration drip that costs you a modest amount to assemble can retail for $100–$200+.

But don’t confuse gross margin with what you keep. Once you add rent, nursing labor, medical direction, and marketing, net margins land closer to 20–40% for fixed clinics (directional, synthesized across operator sources). Treat the “50–80% profit” claims floating around the internet with healthy skepticism — they almost always ignore overhead.

The lesson: your menu architecture, labor model, and sourcing — not the price of the saline bag — decide whether you’re actually profitable.

Architect the Menu in Two Tiers

A profitable menu is deliberately simple. Complexity kills bookings and complicates your inventory.

Tier 1 — Anchor drips (volume). Accessible, fast-moving, easy to staff:

• Basic hydration / saline + electrolytes — typically $79–$250
• Myers’-style vitamin cocktail — typically $150–$400
• A clean “recovery” or “wellness” base

These anchor drips bring people in the door.

Tier 2 — Premium add-ons (margin). Higher price, longer chair time, real differentiation:

• NAD+ infusions — frequently $350–$1,000+
• Glutathione, high-dose vitamin C, and targeted “boost” injections bundled onto an anchor drip

Industry coverage consistently names NAD+ and glutathione as the highest-margin add-ons — and bundling is the single biggest lever on per-visit revenue in a booming vitamin-IV category. With the average U.S. session reported around $280 (directional industry figures), every add-on you attach moves you above the mean.

Price on Value, Then Lock In Recurring Revenue

Don’t price off a cost-plus markup — price off positioning. A premium, professional experience supports a premium price; racing competitors to the bottom destroys the margin that makes the business work.

Then capture recurring revenue, because the membership segment is growing fastest for a reason:

• Cost-per-drip memberships trade a modest discount for predictable monthly revenue and higher visit frequency.
• Seasonal and bundled packages smooth cash flow and lift retention.

Memberships convert one-time walk-ins into a forecastable revenue base — which also makes your inventory planning dramatically easier.

Source to Protect Margin and Your License

This is the part generic “IV is profitable” articles skip — and it’s where margin quietly turns into liability if you get it wrong.

• 503A vs. 503B. 503A pharmacies require patient-specific prescriptions and can’t batch for office use. For ready-to-administer office stock, 503B outsourcing facilities are the federally compliant route — but your state board can restrict office-use compounding even when federal law allows it, and “other IV bars do it” is not a defense.
• USP <797> beyond-use dating. Sterile preparations have strict beyond-use dates driven by the compounding environment — so you can’t pre-mix the week’s drips and store them indefinitely. This is a real formulary-planning constraint.
• DSCSA. A clinic that buys and administers prescription drugs is a “dispenser” and must trade only with licensed partners. Full track-and-trace obligations phase in through November 27, 2026 — so vet your vendors now.
• Vet for sterility history. The FDA issued 2024–25 warning letters to compounders for insanitary conditions and sterility failures, including large recalls. Who you source from is a patient-safety and liability decision, not just a price decision.

Name the Menu Carefully — the FTC Reads Menus Too

How you describe a drip is regulated. The FTC requires competent and reliable scientific evidence for health claims, and it has acted against IV providers — including a Texas hydration bar ordered to stop claiming its cocktails treat serious diseases. Name drips around the experience and ingredients — not disease treatment.

And remember the labor side: most states require a provider’s good-faith exam and order before administration, and many require a medical director. That structure is both a compliance requirement and a real cost line in your margin model.

Your Profitable-Menu Checklist

• Two tiers: a few accessible anchor drips + premium high-margin add-ons.
• Model net margin, not gross — include labor and medical direction.
• Bundle add-ons to lift the average ticket above ~$280.
• Launch a membership to capture recurring revenue and ease inventory planning.
• Confirm 503A/503B sourcing for every injectable, per your state board.
• Respect USP <797> beyond-use dating in your prep workflow.
• Use DSCSA-licensed, sterility-vetted suppliers.
• Name and market the menu inside FTC limits.

Build a Menu That Protects Your Margin — and Your License

USA MedPremium supplies licensed clinics and med spas with traceable, compliantly sourced IV ingredients and supplies — ready-to-administer, DSCSA-compliant, and vetted for quality — so your margin never becomes a liability. Stock your program from our IV Therapy and Pharmacy categories.

Register for a wholesale business account to view pricing and build your formulary, or contact our procurement team to plan compliant supply for your menu.

Related reading:

• The 2026 IV Therapy Sourcing Playbook: How Compliant Clinics Buy Smarter
• Mobile & Membership IV: The Two Models Driving Clinic Growth in 2026
• NAD+ IV Therapy: The Premium Service Behind 2026’s Highest Margins
• The Longevity IV Boom: How to Ride It Without Risking Your License

Sources

• Grand View Research — Intravenous Hydration Therapy Market Report
• Research and Markets — Intravenous (IV) Therapy Membership Global Market Report 2026
• Inc. — Shoot It Into My Veins: What’s Fueling the Vitamin IV Craze
• U.S. FDA — Hospital and Health System Compounding Under Section 503A
• The FDA Group — 503A vs. 503B Compounding Pharmacies
• U.S. Pharmacopeia — General Chapter <797> Sterile Compounding
• U.S. FDA — Drug Supply Chain Security Act (DSCSA)
• U.S. FDA — Warning Letter, Empower Pharmacy (April 2, 2025)
• U.S. FTC — Health Claims
• American Med Spa Association — Update to Laws Regarding IV Therapy in Medical Spas